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1  | INTRODUCTION
Venous thrombosis is the collective term for deep vein thrombo-
sis and pulmonary embolism, indicating the presence of a blood 
clot obstructing flow in the deep veins or pulmonary arteries, re-
spectively. At an estimated incidence rate of 1- 2 per 1000 persons 
every year, it is the third most common cardiovascular disease 
and is associated with substantial short- and long- term morbidity 
and mortality.1–4 Short- term consequences of venous thrombosis 
include the absolute need for anticoagulant therapy, which is in-
evitably associated with an increased bleeding risk5; the estimated 
case- fatality rate is approximately 6% after 30 days.2 Long- term 
consequences concern the risk of disease recurrence, as approx-
imately 20- 25% of all patients have a recurrence within 5 years.6 
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Abstract
Venous thrombosis is a major contributor to the global disease burden. In this review 
we aim to answer two important questions: (1) are we making progress in reducing 
this disease burden and (2) how can we further improve? To answer these questions, 
we first evaluated the disease burden, that is, the incidence of first venous thrombo-
sis over the past decade(s) and discuss its most important determinants. We found 
that the incidence of first venous thrombosis remained relatively unchanged, despite 
an increase in risk factor prevalence and a rise in identification of subsegmental pul-
monary emboli due to enhanced image quality and utilization. This is, however, bal-
anced by improved thromboprophylaxis strategies, resulting in an overall unchanged 
venous thrombosis incidence. We can further improve by developing, validating, and 
implementing risk assessment strategies, allowing us to identify persons at high or 
low risk in whom thromboprophylaxis can be provided or withheld, respectively.
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Essentials
• The incidence of venous thrombosis has remained stable over the past decade.
• Risk factors and diagnostic and prophylaxis strategies are determinants of the overall incidence.
• Given current trends of the determinants, we are making progress in reducing the burden.
•	 More	progress	can	be	made	by	implementing	validated	risk	assessment	models.
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Other long- term consequences include the risk of developing post- 
thrombotic syndrome (PTS, in 20- 50% of patients with a deep vein 
thrombosis)7 and the rare but potentially life threatening condition 
chronic thromboembolic pulmonary hypertension (CTEPH) that 
occurs in approximately 0.6% of patients with pulmonary embo-
lism.8 Venous thrombosis is a leading cause of disability- adjusted 
life years (DALYs) lost9 and associated with substantial healthcare 
costs.10,11 In the past decades, several changes in the prevention, 
diagnostic strategies, and management of venous thrombosis have 
been achieved. For instance, guidelines now suggest extended or 
lifelong duration of anticoagulant therapy in men with a first unpro-
voked event, while previously, a limited treatment duration was rec-
ommended for these patients.12 Pulmonary embolism is now almost 
always diagnosed with computed tomography (CT) angiography or 
ventilation perfusion scan instead of (the gold standard) pulmo-
nary angiography,13 and for several risk situations, such as surgery, 
near- universal thromboprophylaxis strategies have been imple-
mented.14–16 In addition, the prevalence of risk factors for venous 
thrombosis in populations is continuously changing. There is an 
epidemic of obesity in the aging Westernized population in which, 
for instance, 32.5% of the adult population in the Netherlands was 
overweight	(body	mass	index	[BMI]	≥	25	kg/m2) in 1995 which in-
creased to 41.7% in 2010,17 while the use of hormone replacement 
therapy in women over 50 has declined after it was shown in the 
early 2000s that such therapy increases both the risk of arterial 
cardiovascular disease as well as venous thrombosis.18,19 Therefore, 
it is important to evaluate the burden of venous thrombosis over 
time, to assess whether we are making progress in the prevention 
of this disease and to find leads as to how we can reduce the venous 
thrombotic disease burden even further. In this article, by reviewing 
the available evidence including state of the art research presented 
at the International Society on Thrombosis and Haemostasis (ISTH) 
Congress 2017, we aim to answer two questions: (1) are we making 
progress in decreasing the burden of venous thrombosis in the gen-
eral population, and (2) how can we proceed further in preventing 
venous thrombosis disease in the community?
2  | VENOUS THROMBOSIS INCIDENCE 
OVER TIME
One of the ways to evaluate disease burden is by studying its inci-
dence (number of persons who get the disease in a population at 
risk, per size of the population and a given time period). However, 
the total burden of the disease goes beyond first events, as it also 
includes post- thrombotic syndrome, anticoagulant treatment, mor-
tality, recurrent events and health- care associated costs. To esti-
mate the total burden, we will therefore consider the first event as a 
“marker” of the total burden of thrombotic disease that follows after 
a first event. For this, we need data on trends on venous thrombosis 
incidence from populations- based studies.
In a United States population- based study by Heit and col-
leagues, the average age- and sex- adjusted incidence of a first 
venous thrombosis in the Olmsted County population was 
10.2 (95% CI 10.2- 10.3) per 10 000 person- years which did 
not change over the course of 30 years (1981- 2010 based on 
3293 events, Figure 1A).3 In contrast, in another population- 
based study from the United States, Huang and colleagues 
showed that the age- and sex- adjusted incidence of a first event 
increased in the period 1985- 2009 from 7.3 (95% CI 6.4- 8.2) 
per 10 000 person- years to 13.3 (95% CI 12.2- 14.3), based on 
3887 events (Figure 1B). The authors observed that the rise was 
mainly due to an increase in the incidence of pulmonary embo-
lism.20 Alotaibi and colleagues assessed the incidence of venous 
thrombosis over calendar- time in Alberta, Canada (4 million in-
dividuals).21 Between 2004 and 2012 there were 31 656 inci-
dent acute venous thrombosis events, with an overall age- and 
sex- standardized incidence rate of 13.8 (95% CI 13.7- 14.0) per 
10 000 person- years. This incidence rate did not change during 
the study period.21 In the Norwegian Tromsø study, in which 
26 855 persons aged 25- 97 were followed from 1994/1995 
throughout 2012, the incidence of a first symptomatic venous 
thrombosis (based on 693 events) increased from 15.8 (95% CI 
11.6- 19.9) per 10 000 persons years in 1996 and 1997 to 20.1 
(95% CI 16.0- 24.3) in 2010 and 2011.22
To investigate the incidence of first venous thrombosis events 
over calendar time in the Netherlands, we conducted a dynamic 
population- based study between 2003 and 2012, as was previ-
ously described by Kort et al.23,24 Since only patients treated with 
vitamin K antagonists are included in the study, patients using long 
term low- molecular- weight heparins for venous thrombosis treat-
ment (such as patients with a malignancy or pregnant patients) are 
underrepresented. Patients who died as a result of or shortly after 
the event are therefore neither in the study. The results of this 
study were presented at the ISTH congress of 2017, as depicted 
in Figure 1C (adapted from Scheres et al.24), from which it appears 
that, based on these 14 253 events, the overall age- adjusted in-
cidence rate of first venous thrombosis did not change over the 
course of 10 years.
Taken the results from these five studies together, it can be con-
cluded that the incidence of (diagnosed) first venous thrombosis 
remained relatively unchanged over the past decades. This would 
suggest that we are not making progress in preventing venous 
thrombotic disease in the general population. However, such an in-
terpretation might be too superficial and we first need to examine 
the determinants of these incidences more closely.
3  | DETERMINANTS OF VENOUS 
THROMBOSIS INCIDENCE
The three main determinants that can influence the incidence of ve-
nous thrombosis in a general population are: (1) the prevalence of 
risk factors for venous thrombosis, (2) the number and method of 
diagnostic procedures, and (3) the implementation of thrombophro-
phylactic strategies.
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3.1 | Prevalence of risk factors
The incidence of any disease is dependent on the prevalence of risk 
factors in the population at risk for the disease. Obviously, when 
more individuals have (multiple) risk factors, the more likely it be-
comes that these individuals will actually get the disease.
For venous thrombosis, risk factors can roughly be classified 
into two main categories, ie, acquired and genetically determined.25 
Acquired risk factors can be either transient or persistent. Transient 
risk factors are only present for a certain time period, such as, for 
example, long- haul flights or pregnancy and the postpartum period. 
Examples of persistent acquired risk factors are inflammatory bowel 
disease or overweight and obesity. Genetically determined risk fac-
tors are non- modifiable and always present such as male sex, muta-
tions leading to thrombophilia or body height.25
In Table 1, risk factors for first venous thrombosis that we 
discuss in this review are shown. In addition, we have indicated 
whether we anticipate an increase or decrease in the prevalence 
of these risk factors in Western countries in coming years. As an 
example, trends in the prevalence of these risk factors over calen-
dar time in the Netherlands are shown in Figure 2, based on data 
provided by Statistics Netherlands,17,26–30 Royal Schiphol Group,31 
and the Netherlands Comprehensive Cancer Organisation.32 In the 
near future, the prevalence of most of these risk factors is likely 
to increase further. As shown in Figure 2, the number of total hos-
pitalizations and persons with an active malignancy has increased 
over the years (1.4- 1.5 fold, respectively, when comparing the 
year 2010 with 1995). A similar pattern was described by Torre 
and colleagues in 2015, who observed an increase in global can-
cer  prevalence.33 In 1995, 13.7% of the Dutch population was aged 
F IGURE  1 Absolute risk of first 
venous thrombosis over the course of 
time in three independent studies. Age- 
adjusted incidence rates of first venous 
thrombosis: A, among Olmsted County, 
Minnesota	residents,	1981-	2010	based	
on 3293 events as published by Heit 
and colleagues,3 printed with permission 
from Schattauer publishers; B, among 
residents	of	Worcester,	Massachusetts,	
1985- 2009 based on 3887 events, printed 
with permission of Elsevier as published 
by Huang and colleagues20; and C, over 
the course of 10 years in three large 
anticoagulation clinics in the Netherlands, 
adapted from Scheres et al.,24 based on 14 
253 events
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>65, which increased to 16.0% in 2010. This is in concordance with 
the global aging of the population, as reported by the Global Aging 
Institute.34 The population was more often overweight/obese 
in 2010 than in 1995, in line with reports from the World Health 
Organization (WHO), describing a global increase of overweight 
and obese populations.35 Air travel from the main airport terminal 
in the Netherlands (Schiphol, Amsterdam) has nearly doubled from 
1995 to 2010, a similar trend can be observed from data on world-
wide air travel from the World Data Bank.36 Both the total num-
ber of surgeries as well as high- risk venous thrombosis surgeries, 
such as total knee and hip replacements, increased from 1995 to 
2010 in the Netherlands, where the number of knee replacements 
more than doubled over this timeframe. An increase in the global 
surgery volume was also reported by the WHO.37 In contrast, oral 
or injectable contraceptive use among women <50 years declined 
slightly and the number of live birth pregnancies was constant over 
time. However, the number of live birth pregnancies in women 
aged 40 years or older increased two- fold from 1995 to 2010, who 
carry a higher risk for venous thrombosis than pregnant younger 
mothers.38–40 In a 2015 report by the United Nations, a slight global 
decrease in the number of pregancies is projected globally in the 
coming decades, where especially in Western countries, the mater-
nal age at chilbirth is increasing.41 In addition, at the ISTH congress 
of 2017, O’Shaughnessy et al. reported on venous thrombosis risk 
factors in 16 218 women who delivered at the Rotunda Hospital 
in Dublin between September 2014 and December 2016. The ma-
jority, i.e, 82% of women, had at least one venous thrombosis risk 
factor (on top of pregancy) and over half of the women had two or 
more risk factors. Of all 16 218 women, 5380 (33.2%) were 35 years 
or older.42
Overall, the prevalence of these risk factors is increasing and 
many of these risk factors are currently unavoidable.
3.2 | Diagnostic procedures
Second, the incidence of venous thrombosis is dependent on the 
number of events identified. An increase in the number of imag-
ing tests will result in an increased number of encountered (either 
symptomatic, asymptomatic or misclassified) events. As was previ-
ously described by Wiener and colleagues, there has been a rise in 
the use of CT pulmonary angiograms with increasing availability of 
CT, as it also allows finding other causes for pulmonary embolism–
like symptoms. At the same time, the image quality is continuously 
improving, resulting in finding more smaller (subsegmental) pulmo-
nary emboli and hence, an increase in incidence. In contrast, the 
age- adjusted, in- hospital case- fatality rate of pulmonary embolism 
decreased from 12.1% in 1998 to 7.8% in 2006. This suggests that 
at least some of these pulmonary emboli are self limiting or misclas-
sified events.43,44 A similar observation was reported by Dentali 
and colleagues, in a study on admission for pulmonary embolism in 
TABLE  1 Venous thrombosis risk factors and anticipated change of prevalence the coming years
Risk factor
Estimated relative risk (compared to the 
general population)*
Anticipated prevalence 
increasing or decreasing
References for 
change in prevalence
Provoked, Transient
General, orthopedic surgery and 
hospitalization
5- 50 ↑ [26,	27,	37]
Long- haul (air) travel 2.5- 3 ↑ [31,	36]
Infections 1- 3 ↑ [27]
Pregnancy and postpartum period 3- 5 ↓/(↑	older	maternal	age) [28,	41]
Oral contraceptive use 4- 7 ↓ [29]
Hormone replacement therapy 2- 5 ↓ [73]
Provoked, Persistent
Overweight and obesity 2- 3 ↑ [17,	35]
Active malignancy 7- 20 ↑ [32,	33]
Chronic (inflammatory) diseasesa 1- 10 ↑ [74,	75]
Unprovoked
Increasing age 1-	∞ ↑	(older	population) [30,	34]
Body height 1.5- 4 =/↑	(global	increase) [17,	76]
Male	sex 2 = [30]
Genetic risk factorsb 1- 20 = [77,	78]
↑;	increase.	↓;	decrease.	=;	no	change.	*List	of	risk	factors	and	relative	risk	adapted	from	Lijfering	et	al.79
aChronic kidney diseases, Human immunodeficiency virus, hyperthyroid disease, inflammatory bowel disease, systemic lupus erythematosus, amongst 
others.
bFactor V Leiden mutation, Prothrombin G20210A mutation, genetic deficiencies of protein S, protein C, or antithrombin, non–O blood group amongst 
others.
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a region with approximately 13 million inhabitants in Italy, where 
the incidence of pulmonary embolism increased between 2002 and 
2012 from 4.0 to 6.2 per 10 000 persons per year in women and 
from 3.5 to 4.6 in men. The case- fatality rate decreased over this 
time frame (from 15.6% to 10.2% in women and from 17.6% to 10.2% 
in men).45 In the Netherlands, we also observed an increase in pul-
monary embolism diagnoses over calendar time, but a decrease in 
incidence of deep vein thrombosis (Figure 3), resulting in an overall 
unchanged incidence rate of first venous thrombosis. A similar ob-
servation was reported previously by Huang and colleagues, in their 
study among residents from Worcester in the United States from 
2001 the incidence of (distal or proximal) first deep vein thrombo-
sis decreased and the incidence first pulmonary embolism increased 
(Figure 1B).20 In parallel with this observation, there was an increase 
in noninvasive testing between 1985 and 2009. Notably, after 2005 
the incidence of first (distal or proximal) deep vein thrombosis also 
seemed to increase again.20 A comparable finding was reported 
based on data from the United States Healtcare Cost and Utilization 
Nationwide Inpatient Sample, in which the hospitalization rates for 
pulmonary embolism increased from 1996 to 2014. The hospitaliza-
tion rates for deep vein thrombosis initially increased up to 2012 
and decreased afterwards.46 These observations also are in line 
with a report from the Norwegian Tromsø study that showed that 
the incidence of pulmonary embolism increased from 4.5 (95% CI 
F IGURE  2 Trends	in	the	prevalence	of	several	risk	factors	for	venous	thrombosis,	1995-	2010.	*Reference	is	1995	except	for	
contraceptives (oral or injectable) where the reference year is 1998. A denotes, major medical conditions; B, demographics and lifestyle; C, 
surgery (all) and orthopedic surgery; D, female- specific risk factors. Adapted from statistics Netherlands,17,26–30 Royal Schiphol Group,31 and 
Netherlands Comprehensive Cancer Organisation.32 Precise numbers are available in Table S1
100
50
0
–50 1998 2001 2004 2007 2010
250
200
150
100
50
0
–50 1998 2001 2004 2007 2010 –50 1998 2001 2004 2010 20132007
Contraceptives (oral or injectable)
Live birth pregnancies
Maternal age >40 years
1998 2001 2004 2007 2010
100
150
100
50
0
–50
0
50
Overweigth/obesity (BMI≥25 kg/m2) 
Flights from Amsterdam
Population aged >65 years 
Invasive malignancy
Pneumonia hospital admission
Hospital admission (total)
R
el
at
ive
 c
ha
ng
e 
(%
)*
R
el
at
ive
 c
ha
ng
e 
(%
)*
R
el
at
ive
 c
ha
ng
e 
(%
)*
R
el
at
ive
 c
ha
ng
e 
(%
)*
Surgeries (total)
Total knee replacements
Total hip replacements
(A) (B)
(C) (D)
F IGURE  3 Absolute risk of first deep vein thrombosis and 
pulmonary embolism over the course of time in three large 
anticoagulation clinics in the Netherlands. Incidence of first 
pulmonary embolism and deep vein thrombosis over the course of 
10 years in three large anticoagulation clinics in the Netherlands24
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2.3- 6.7) per 10 000 person- years in 1996 and 1997 to 11.3 (95% CI 
8.2- 14.4) in 2010 and 2011, where the incidence of isolated deep 
vein thrombosis decreased during this timeframe, from 11.2 (95% 
CI 7.7- 14.6) per 10 000 person years in 1996 and 1997 to 8.8 (95% 
CI 6.1- 11.5) in 2010 and 2011.22 It is currently uncertain whether 
patients with subsegmental pulmonary emboli (either symtomatic or 
asymptomatic and outside of special patients groups) benefit from 
anticoagulant treatment. For this purpose, an international cohort 
management study currently investigates the safety of withholding 
anticoagulants in these patients (NCT01455818).
Although incidence data over time are limited, the increase in 
use of whole- leg ultrasound as opposed to the use of only proximal 
ultrasound has likely led to an increase in identification of distal 
deep vein thromboses. Although these can present with trouble-
some symptoms, distal deep vein thromboses are less burden-
some than proximal deep vein thrombosis as they are  associated 
with a lower recurrence and mortality rate.47,48 Whether patients 
(outside of special patient groups) with symptomatic distal deep 
vein thromboses benefit from anticoagulation therapy is cur-
rently debated.49,50 Consequently, in centers in which patients 
with distal deep vein thrombosis are treated with anticoagulants, 
whole- leg ultrasound is often used, whereas in centers where dis-
tal deep vein thrombosis is typically not treated, only proximal 
ultrasound is used. For this reason, distal deep vein thromboses 
are often not or only partly included in incidence studies. In con-
trast, there is strong evidence and global consensus for several 
decades that proximal deep vein thrombosis necessitates treat-
ment with  anticoagulant therapy. Therfore, the incidence of prox-
imal deep vein thrombosis over the past years will not have been, 
or only slighty, affected by changes in diagnostic and treatment 
strategies.
In summary, the overall incidence of first venous thrombosis 
is dependent on the number of imaging tests performed. In the 
past few years there has been an increase in imaging quality and 
the number of diagnostic tests performed which has especially 
resulted in an increased number of (subsegmental) pulmonary em-
boli diagnoses. In contrast, the incidence of proximal deep vein 
thrombosis has decreased.
3.3 | Prophylactic strategies
Third, the incidence of venous thrombosis is influenced by the 
usage of tromboprophylactic strategies. Increasing the use of 
thromboprophylaxis will decrease the number of venous thrombo-
sis events. Prophylactic strategies can be implemented for high- 
risk situations, such as hospitalization, medical illness, orthopedic 
surgery, trauma or pregnancy. As it is challenging, if not currently 
impossible, to use prophylaxis to prevent unprovoked trombotic 
events (since there is no preceding high- risk situation that can be 
identified or anticipated on in these individuals), the efficacy of 
prophylactic strategies can only be inferred from assesing the inci-
dence of provoked events over calender time because if profylac-
tic strategies are succesful, this should be reflected by a decline in 
provoked events. This is indeed the case, as was shown by Heit and 
colleagues, who reported a decline in the incidence of provoked 
first venous thrombotic events from 1981- 2010.3 In addition, the 
implementation of a nationwide program for venous thrombosis 
prevention in England has resulted in a risk assesment in over 95% 
of patients admitted to an acute National Health Service hospital.51 
In a subsequent study by Roberts and colleagues, it was shown that 
succesful risk assesment was also associated with a reduction in 
hospital- associated venous thrombosis events in England; risk ratio 
0.88 (95% CI 0.74- 0.98).51,52
In brief, thromboprophylaxic strategies seem efficacious in re-
ducing the incidence of venous thrombosis, when correctly and 
rigourously applied.
Determinant
Increase results in 
↓/↑ incidence
Decrease results in 
↓/↑ incidence
Current indicator that we 
are making progress
Prevalence of 
risk factors
↑ ↓ Despite an increase in risk 
factor prevalence, venous 
thrombosis incidence 
remained unchanged
Number and 
quality of 
diagnostic tests
↑ ↓ Despite a rise in identifica-
tion of subsegmental 
pulmonary emboli, venous 
thrombosis incidence 
remained unchanged
Usage of 
thrombo-
prophylaxis 
strategies
↓ ↑ More	and	better	thrombo-
prophylaxis strategies 
balance the rise in risk 
factors and number of 
diagnostic tests, resulting 
in an overall unchanged 
venous thrombosis 
incidence
↑;	increases	the	venous	thrombosis	incidence.	↓;	decreases	the	venous	thrombosis	incidence.
TABLE  2 Summary of the 
determinants of venous thrombosis 
incidence, the direction of their effect and 
current indicators that we are making 
progress
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4  | ARE WE MAKING PROGRESS?
To answer the question whether we are making progress one needs 
to combine knowledge on the epidemiological patterns of the ve-
nous thrombosis burden with knowledge on its determinants. This 
way, we can observe progress in three ways (summarized in Table 2). 
First, despite an increase in the prevalence of most risk factors, the 
incidence remained relatively unchanged over the past years: this 
means we must have made progress, otherwise the incidence would 
have increased in concordance with the rise in prevalence of risk fac-
tors. Second, over the years the incidence of pulmonary embolism 
has increased, due to the finding of more subsegmental pulmonary 
emboli.43–45 In addition, the incidence of proximal deep venous 
thrombosis, which has not been subject to changes in diagnostic 
management, seems to decline. As the overall incidence remains un-
changed, a portion of deep venous thrombosis and pulmonary em-
boli must have been prevented, and “replaced” by less burdensome 
(subsegmental) or misclassified pulmonary emboli. Hence, there is 
progress. Third, over the years several thromboprophylaxis strate-
gies have been implemented that resulted in a reduction of the num-
ber of hospital associated thromboses.51,52 Taken together, although 
the incidence of venous thrombosis did not go down, we are making 
progress. There is, nevertheless, room for advancement, which we 
will discuss below.
5  | HOW CAN WE FURTHER IMPROVE?
5.1 | Prevention of first venous thrombosis
Knowledge on incidence of venous thrombosis and its determinants 
is useful for two purposes: (1) better understanding of the patho-
physiology of venous thrombosis, and (2) prevention of venous 
thrombosis. However, for the latter, we are restricted to prevention 
of provoked events, as individuals at risk for unprovoked thrombosis 
are hard to identify. For individuals at risk of provoked events, the 
risk can be reduced whilst the provoking risk factor is in play. For 
example, patients undergoing major (orthopedic) surgery receive 
prophylaxis for a certain period after the surgery. Such prophylactic 
strategies can be implemented in two ways, either in all patients dur-
ing a high- risk situation or limited to patients with actual (estimated) 
high risk of an event during the high- risk situation.
5.2 | General prophylaxis in high- risk situations
This first possible strategy, which is currently applied, is to pro-
vide thromboprophylaxis to all patients during a high- risk situation. 
This is frequently done when the duration of the risk situation is 
relatively short and thromboprophylaxis is easily administered, for 
example in immobilized patients admitted to the hospital or in pa-
tients recovering from major surgery.15,16,53 This strategy is more 
challenging and impractical when the high- risk situation is of longer 
duration, for example during pregnancy in women with inherited an-
tithrombin deficiency,54 or in patients with an active malignancy.55 
Moreover,	 the	 longer	 patients	 receive	 prophylaxis,	 the	 higher	 the	
chances of a bleeding event. In addition, we have to keep in mind 
that the absolute risk of an event can still be relatively low, gener-
ally a few percent. Hence, there are many patients in high- risk situ-
ations who will not develop a venous thrombosis, possibly not even 
without prophylaxis. To complicate matters even further, there will 
be patients who will develop thrombosis, despite taking prophylaxis. 
As an example, in a Cochrane review on thromboprophylaxis after 
major orthopedic surgery, 2% of patients developed venous throm-
bosis despite thromboprophylaxis with low- molecular- weight hepa-
rin.56 In addition, in the POT- KAST and POT- CAST trials low- dosed 
thromboprophylaxis was compared with no thromboprophylaxis for 
preventing symptomatic venous thrombosis in patients who under-
went knee arthroscopy for the duration of eight days and for the 
full period of immobilization patients with casting of the low leg, 
respectively. There was no difference in the incidence of the pri-
mary outcome, ie, symptomatic venous thrombosis, between both 
arms in these trials. In the treatments arms of these trials, throm-
boprophylaxis did not prevent thrombosis in 0.7% (POT- KAST) and 
1.4% (POT- CAST) of the patients, respectively.57 In line with this, the 
aforementioned study on the risk assessment program after achiev-
ing coverage of >90% of hospitalized patients being risk assessed 
in England resulted in fact in only a small risk reduction, risk ratio 
0.88 (95% CI 0.79- 0.98), of hospital associated thrombosis.52 In an-
other study, investigators set out to assess the effect of achieving 
nearly	universal	thromboprophylaxis	use	at	the	Mayo	Clinic	hospital	
(Rochester,	MN,	USA)	on	incidence	of	in	hospital	venous	thrombosis	
(defined as events which occurred in the hospital or within 92 days 
after any hospital discharge) over the years 2005- 2010.14 The au-
thors concluded that, as the incidence remained unchanged, de-
spite an increase in the rate of thromboprophylaxis to ~90% near 
the midpoint of the study period, the thromboprophylaxis had been 
insufficient.14
Overall, general (low- dosed) thromboprophylaxis strategies do 
not seem sufficient for all high- risk patients. An obvious explanation 
for this observation is that venous thrombosis is a multicausal dis-
ease, implying that several risk factors need to be present to reach 
a certain “thrombosis threshold” and the disease to occur.58 The 
number of risk factors present in an individual, however, is likely be 
different among individuals. Furthermore, the risk in an individual is 
also dependent on the strength of the risk factors present. As illus-
trations, in women using oral contraceptives, the activated protein 
C (APC) resistant effects may increase the risk of a venous throm-
bosis synergistically when a prothrombotic mutation such as Factor 
V Leiden is also present.59 In a different example, the increased risk 
of venous thrombosis is stronger in tall and short persons than per-
sons of average size during long haul flights, likely because they are 
more prone to obstructed blood flow due to the unnatural sitting 
circumstances.60 In summary, venous thrombosis can result from 
different combinations of risk factors, where some combinations 
result in stronger effects than others and can vary among patient 
characteristics. This can explain why some patients develop throm-
bosis despite anticoagulant treatment, while many others never 
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develop it, even in the absence of treatment. This concept suggests 
the need for an individualized approach. Combining and integrating 
knowledge on the presence of predisposing factors in individuals in 
statistical models, should ideally lead to the possibility to determine 
the size of the risk of venous thrombosis in a particular patient in a 
particular situation.
5.3 | Risk prediction tailored prophylaxis
To further improve the current situation and continue to reduce the 
number of venous thrombosis evens, risk assessment models (also 
known	as	prediction	models	or	RAMs)	seem	promising.	These	mod-
els ideally allow identification of individuals at high or low venous 
thrombosis risk during a specific risk situation.61 In recent years, 
several models have been developed for different patient popula-
tions such as patients with cancer62 on which a novel model was 
also presented at the ISTH 2017 congress by Pabinger and col-
leagues,63 major trauma,64 lower extremity cast- immobilization,65 
medical inpatients,66 or postpartum women,67 among others. In 
order to optimize the safe utilization of these models, they first 
need to be externally validated (ie, tested in a dataset different from 
the	set	in	which	the	models	were	built).	Models	may	seem	to	per-
form well in the dataset in which they were built, but performance 
is often limited in external validation studies (even when the target 
population for the model is similar).68 Next, models can be improved 
by studying the potential added value (so called incremental value 
studies) of a new predictor which was not yet used in the initial 
version of the model.69 A potential pitfall in the era of risk assess-
ment models is when all efforts are aimed towards the develop-
ment of new separate models instead of focusing on the validation 
and improvement of currently available models. In a systematic re-
view on available risk assessment models for cardiovascular disease 
in the general population it was shown that there is an excess of 
separate models (n = 363).70	Moreover,	 external	 validation,	 incre-
mental value studies or studies comparing the performance of mod-
els were often not performed.70 Although this systematic review 
excluded venous thrombosis models and a systematic overview of 
venous thrombosis models is lacking, the same challenges apply. As 
an example, at the ISTH congress of 2017, Blondon and colleagues 
presented the results of an external validation and comparison to 
the	Geneva	RAM	of	the	Improve	RAM	for	thromboprophylaxis	for	
acutely ill medical patients.71 Finally, to actually achieve a reduc-
tion in the venous thrombosis burden by preventing events by using 
these models, efforts towards the implementation and prospective 
evaluation (eg, impact studies) of well performing available mod-
els are necessary.72 In brief, we can further proceed in reducing 
the burden of venous thrombosis by the development, validation, 
and implementation of well- performing risk assessment models 
that will allow identification of patients who require (duration and 
dose tailored) thromboprophylaxis. As general (low- dose) thrombo-
prophylaxis does not seem effective in all high- risk patients, trials 
are needed to determine the optimal dose and duration of thrombo-
prophylaxis in these patients.
6  | CONCLUSION
To conclude, we are definitely making progress in reducing the venous 
thrombosis burden. This progress can be deduced from a relatively un-
changed incidence rate over the past decade(s), despite an increasing 
prevalence of risk factors and identification of subsegmental emboli. 
This progress can be attributed to better and more frequent imple-
mentation of thromboprophylaxis strategies which have resulted in a 
reduced number of events in patients during high- risk situations. We 
can likely proceed further by developing, validating, and implement-
ing risk assessment strategies, in which persons at high- risk during risk 
situations can be identified and prescribed adequate thromboprophy-
laxis, whereas in patients at low risk prophylaxis can be safely withheld.
ACKNOWLEDGMENTS
We are grateful to Helga Vermaas, Nynke Wiersma, and Felix van der 
Meer	from	the	anticoagulation	clinics	from	The	Hague,	Utrecht,	and	
Leiden, respectively, for providing the data which were reviewed in 
this article.
RELATIONSHIP DISCLOSURE
None of the authors have any disclosures relevant to this paper.
ORCID 
Luuk J. J. Scheres  http://orcid.org/0000-0001-5282-5520 
Suzanne C. Cannegieter  http://orcid.org/0000-0003-4707-2303  
REFERENCES
 1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mor-
tality from venous thromboembolism in a real- world population: 
the	Q-	VTE	Study	Cohort.	Am	J	Med.	2013;126:832.e13–e21.
 2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, 
Rosendaal FR, Hammerstrom J. Incidence and mortality of ve-
nous thrombosis: a population- based study. J Thromb Haemost. 
2007;5:692–9.
	 3.	 Heit	JA,	Ashrani	A,	Crusan	DJ,	McBane	RD,	Petterson	TM,	Bailey	
KR. Reasons for the persistent incidence of venous thromboembo-
lism. Thromb Haemost. 2017;117:390–400.
 4. Delluc A, Tromeur C, Le Ven F, et al. Current incidence of venous 
thromboembolism and comparison with 1998: a community- based 
study in Western France. Thromb Haemost. 2016;116:967–74.
	 5.	 van	Es	N,	Coppens	M,	Schulman	S,	Middeldorp	S,	Buller	HR.	Direct	
oral anticoagulants compared with vitamin K antagonists for acute 
venous thromboembolism: evidence from phase 3 trials. Blood. 
2014;124:1968–75.
 6. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent 
venous thrombosis. Lancet. 2010;376:2032–9.
 7. Rabinovich A, Kahn SR. The postthrombotic syndrome: current ev-
idence and future challenges. J Thromb Haemost. 2017;15:230–41.
	 8.	 Ende-Verhaar	 YM,	 Cannegieter	 SC,	 Vonk	 Noordegraaf	 A,	 et	 al.	
Incidence of chronic thromboembolic pulmonary hypertension 
after acute pulmonary embolism: a contemporary view of the pub-
lished literature. Eur Respir J. 2017;49:pii: 1601792.
     |  207SCHERES Et al.
 9. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major 
contributor to global disease burden. Arterioscler Thromb Vasc 
Biol. 2014;34:2363–71.
	10.	 Barco	 S,	Woersching	AL,	 Spyropoulos	AC,	 Piovella	 F,	Mahan	CE.	
European Union- 28: an annualised cost- of- illness model for venous 
thromboembolism. Thromb Haemost. 2016;115:800–8.
	11.	 Mahan	CE,	Borrego	ME,	Woersching	AL,	et	al.	Venous	thromboem-
bolism: annualised United States models for total, hospital- acquired 
and preventable costs utilising long- term attack rates. Thromb 
Haemost. 2012;108:291–302.
 12. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for 
VTE disease: CHEST guideline and expert panel report. Chest. 
2016;149:315–52.
 13. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines 
on the diagnosis and management of acute pulmonary embolism. 
Eur Heart J. 2014;35:3033–69.
	14.	 Heit	JA,	Crusan	DJ,	Ashrani	AA,	Petterson	TM,	Bailey	KR.	Effect	of	
a near- universal hospitalization- based prophylaxis regimen on an-
nual number of venous thromboembolism events in the US. Blood. 
2017;130:109–14.
	15.	 Gould	 MK,	 Garcia	 DA,	 Wren	 SM,	 et	 al.	 Prevention	 of	 VTE	 in	
nonorthopedic surgical patients: antithrombotic therapy and 
prevention of thrombosis, 9th ed: American College of Chest 
Physicians evidence- based clinical practice guidelines. Chest. 
2012;141:e227S–77S.
 16. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of 
VTE in orthopedic surgery patients: antithrombotic therapy and 
prevention of thrombosis, 9th ed: American College of Chest 
Physicians evidence- based clinical practice guidelines. Chest. 
2012;141:e278S–325S.
 17. Statistics Netherlands. Statline: height and weight, 1995-2010. 
[updated	2017	November	1].	Available	from	http://statline.cbs.nl/
Statweb/publication/?DM=SLN	 L&PA=81565NED&D1	 =	 0-4&D2	
=	a&D3	=	0-1,5&D4	=	0&D5	=	14-29&HDR=T&STB=G1,G2,G3,G4
&VW=T.
 18. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hor-
mone therapy increases risk for venous thromboembolic disease. 
the Heart and Estrogen/progestin Replacement Study. Ann Intern 
Med.	2000;132:689–96.
 19. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus pro-
gestin for secondary prevention of coronary heart disease in post-
menopausal women. Heart and Estrogen/progestin Replacement 
Study	(HERS)	Research	Group.	JAMA.	1998;280:605–13.
 20. Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular 
trends in occurrence of acute venous thromboembolism: the 
Worcester	VTE	study	(1985-	2009).	Am	J	Med.	2014;127:829–39.
	21.	 Alotaibi	GS,	Wu	C,	Senthilselvan	A,	McMurtry	MS.	Secular	trends	in	
incidence and mortality of acute venous thromboembolism: the AB- 
VTE	population-	based	study.	Am	J	Med.	2016;129:879.e19–e25.
 22. Arshad N, Isaksen T, Hansen JB, Braekkan SK. Time trends in inci-
dence rates of venous thromboembolism in a large cohort recruited 
from the general population. Eur J Epidemiol. 2017;32:299–305.
	23.	 Kort	D,	van	Rein	N,	van	der	Meer	FJM,	et	al.	Relationship	between	
neighbourhood socioeconomic status and venous thromboembo-
lism: results from a population- based study. J Thromb Haemost. 
2017;15:2352–60.
 24. Scheres LJJ, Kort D, van Rein N, et al. Abstract: Sex- specific inci-
dence rates of deep vein thrombosis and pulmonary embolism in 
The Netherlands. Res Pract Thromb Haemost. 2017;1:39–40.
 25. Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle 
PA. Categorization of patients as having provoked or unprovoked 
venous thromboembolism: guidance from the SSC of ISTH. J 
Thromb Haemost. 2016;14:1480–3.
 26. Statistics Netherlands. Statline: clinical surgeries, 
1995-2010[updated	 2017	 November	 1].	 Available	 from	
http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA= 
80386NED&D1	=	0-3&D2	=	0&D3	=	0&D4	=	0,19,22&D5	=	a&H-
DR=T&STB=G4,G1,G2,G3&VW=T.
 27. Statistics Netherlands. Statline: hospital admissions, 
1995-2010	 [updated	 2017	 November	 1].	 Available	 from	
ht tp://s tat l ine .cbs .n l/Statweb/publ icat ion/?DM=SLNL& 
PA=71540ned&D1	=	a&D2	=	0&D3	=	l&D4	=	a&D5	=	0,8,45,91&D
6	=	l&D7	=	0-15&HDR=T,G5,G1,G2,G6&STB=G4,G3&VW=T.
 28. Statistics Netherlands. Statline: births, 1995-2010. [updated 2017 
November	1].	Available	from	http://statline.cbs.nl/Statweb/publica-
tion/?DM=SLNL&PA=37422ned&D1	=	0,4-5,7,9,11,13,17,26,35,40-
41,48&D2	=	45-60&HDR=G1&STB=T&VW=T.
 29. Statistics Netherlands. Statline: birth control, 1993-2013. [updated 
2017	November	1].	Available	 from	http://statline.cbs.nl/Statweb/
publication/?DM=SLNL&PA=37459&D1	=	0-9&D2	=	0&D3	=	a&H-
DR=T&STB=G1,G2&VW=T.
 30. Statistics Netherlands. Statline: sex and age, 1995-2010. [updated 
2017	November	1].	Available	from	http://statline.cbs.nl/StatWeb/
publication/?DM=SLNL&PA=70233ned
 31. Royal Schiphol Group. Traffic and transport figures. [updated 
2017	 November	 1].	 Available	 from	 https://www.schiphol.nl/nl/
schiphol-group/pagina/verkeer-en-vervoer-cijfers/
 32. Netherlands Comprehensive Cancer Organisation. Dutch cancer 
figures	 [updated	 2017	November	 1].	 Available	 from	 http://www.
cijfersoverkanker.nl/selecties/dataset_1/img59fb188268062.
 33. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
 34. Global Aging Institute. About global aging. 2017. [updated 2017 
November	1].	Available	from	http://www.globalaginginstitute.org/
about-gai/about-global-aging.html
 35. World Health Organization. Global Health Observatory data: over-
weight	and	obesity.	2016.	 [updated	2017	November	1].	Avaialble	
from http://www.who.int/gho/ncd/risk_factors/overweight/en/
 36. The World Data Bank. Air transport, passengers carried. [updated 
2017	November	1].	Avaialble	 from	https://data.worldbank.org/in-
dicator/IS.AIR.PSGR
	37.	 Weiser	 TG,	 Haynes	 AB,	Molina	 G,	 et	 al.	 Size	 and	 distribution	 of	
the global volume of surgery in 2012. Bull World Health Organ. 
2016;94:201–209f.
 38. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous throm-
boembolism in pregnancy and the puerperium: incidence and additional 
risk factors from a London perinatal database. BJOG. 2001;108:56–60.
	39.	 Jacobsen	AF,	Skjeldestad	FE,	Sandset	PM.	Ante-	and	postnatal	risk	
factors of venous thrombosis: a hospital- based case- control study. 
J Thromb Haemost. 2008;6:905–12.
 40. Sultan AA, Tata LJ, West J, et al. Risk factors for first venous throm-
boembolism around pregnancy: a population- based cohort study 
from the United Kingdom. Blood. 2013;121:3953–61.
 41. United Nations, Department of Economic and Social Affairs, 
Division P. World fertility patterns 2015. [Accessed 2017 November 
1]	Available	from	http://www.un.org/en/development/desa/popu-
lation/publications/pdf/fertility/world-fertility-patterns-2015.pdf
 42. O’Shaughnessy F, Donnelly J, Cooley S, Bennett K, Ní Áinle F, 
Cleary B. Abstract: VTE Risk Factors in an Irish Urban Obstetric 
Population. Res Pract Thromb Haemost. 2017;1:196–7.
	43.	 Wiener	RS,	Schwartz	LM,	Woloshin	S.	When	a	test	is	too	good:	how	
CT pulmonary angiograms find pulmonary emboli that do not need 
to	be	found.	BMJ.	2013;347:f3368.
	44.	 Wiener	RS,	 Schwartz	 LM,	Woloshin	S.	Time	 trends	 in	pulmonary	
embolism in the United States: evidence of overdiagnosis. Arch 
Intern	Med.	2011;71:831–7.
	45.	 Dentali	F,	Ageno	W,	Pomero	F,	Fenoglio	L,	Squizzato	A,	Bonzini	M.	
Time trends and case fatality rate of in- hospital treated pulmonary 
embolism during 11 years of observation in Northwestern Italy. 
Thromb Haemost. 2016;115:399–405.
208  |     SCHERES Et al.
 46. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and 
stroke statistics- 2018 update: a report from the American Heart 
Association. Circulation. 2018;137:e67–492.
	47.	 Galanaud	JP,	Sevestre	MA,	Genty	C,	et	al.	Incidence	and	predictors	
of venous thromboembolism recurrence after a first isolated distal 
deep vein thrombosis. J Thromb Haemost. 2014;12:436–43.
	48.	 Barco	S,	Corti	M,	Trinchero	A,	et	al.	Survival	and	recurrent	venous	
thromboembolism in patients with first proximal or isolated dis-
tal deep vein thrombosis and no pulmonary embolism. J Thromb 
Haemost. 2017;15:1436–42.
 49. Garry J, Duke A, Labropoulos N. Systematic review of the com-
plications following isolated calf deep vein thrombosis. Br J Surg. 
2016;103:789–96.
	50.	 Righini	M,	Galanaud	JP,	Guenneguez	H,	et	al.	Anticoagulant	 ther-
apy for symptomatic calf deep vein thrombosis (CACTUS): a ran-
domised, double- blind, placebo- controlled trial. Lancet Haematol. 
2016;3:e556–62.
	51.	 Roberts	LN,	Durkin	M,	Arya	R.	Annotation:	developing	a	national	
programme for VTE prevention. Br J Haematol. 2017;178:162–70.
 52. Roberts LN, Porter G, Barker RD, et al. Comprehensive VTE pre-
vention program incorporating mandatory risk assessment re-
duces the incidence of hospital- associated thrombosis. Chest. 
2013;144:1276–81.
 53. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical 
patients: antithrombotic therapy and prevention of thrombosis, 9th 
ed: American College of Chest Physicians evidence- based clinical 
practice guidelines. Chest. 2012;141:e195S–226S.
	54.	 Croles	FN,	Nasserinejad	K,	Duvekot	JJ,	Kruip	MJ,	Meijer	K,	Leebeek	
FW. Pregnancy, thrombophilia, and the risk of a first venous 
thrombosis:	 systematic	 review	 and	 bayesian	 meta-	analysis.	 BMJ.	
2017;359:j4452.
	55.	 Blom	JW,	Doggen	CJ,	Osanto	S,	Rosendaal	FR.	Malignancies,	pro-
thrombotic	mutations,	 and	 the	 risk	of	venous	 thrombosis.	 JAMA.	
2005;293:715–22.
	56.	 Forster	R,	Stewart	M.	Anticoagulants	(extended	duration)	for	pre-
vention of venous thromboembolism following total hip or knee 
replacement or hip fracture repair. Cochrane Database Syst Rev 
2016;3:CD004179.
 57. van Adrichem RA, Nemeth B, Algra A, et al. Thromboprophylaxis 
after	 knee	 arthroscopy	 and	 lower-	leg	 casting.	 N	 Engl	 J	 Med.	
2017;376:515–25.
 58. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 
1999;353:1167–73.
	59.	 Bertina	RM,	Koeleman	BP,	Koster	T,	et	al.	Mutation	in	blood	coag-
ulation factor V associated with resistance to activated protein C. 
Nature. 1994;369:64–7.
 60. Cannegieter SC, Doggen CJ, van Houwelingen HC, Rosendaal 
FR. Travel- related venous thrombosis: results from a large 
population-	based	 case	 control	 study	 (MEGA	 study).	 PLoS	Med.	
2006;3:e307.
	61.	 Moons	 KG,	 Royston	 P,	 Vergouwe	 Y,	 Grobbee	 DE,	 Altman	 DG.	
Prognosis	 and	 prognostic	 research:	 what,	 why,	 and	 how?	 BMJ.	
2009;338:b375.
	62.	 Khorana	 AA,	 Kuderer	 NM,	 Culakova	 E,	 Lyman	 GH,	 Francis	
CW. Development and validation of a predictive model for 
chemotherapy- associated thrombosis. Blood. 2008;111:4902–7.
 63. Pabinger I, van Es N, Heinze G, et al. Abstract: development 
and external validation of a risk assessment model for cancer- 
associated venous thromboembolism. Res Pract Thromb Haemost. 
2017;1:203–4.
	64.	 Ho	 KM,	 Rao	 S,	 Rittenhouse	 KJ,	 Rogers	 FB.	 Use	 of	 the	 Trauma	
Embolic Scoring System (TESS) to predict symptomatic deep vein 
thrombosis and fatal and non- fatal pulmonary embolism in severely 
injured patients. Anaesth Intensive Care. 2014;42:709–14.
 65. Nemeth B, van Adrichem RA, van Hylckama Vlieg A, et al. venous 
thrombosis risk after cast immobilization of the lower extremity: 
derivation and validation of a clinical prediction score, L- TRiP(cast), 
in	 three	 population-	based	 case-	control	 studies.	 PLoS	 Med.	
2015;12:e1001899.
 66. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for 
the identification of hospitalized medical patients at risk for venous 
thromboembolism: the Padua Prediction Score. J Thromb Haemost. 
2010;8:2450–7.
	67.	 Sultan	AA,	West	J,	Grainge	MJ,	et	al.	Development	and	validation	of	
risk prediction model for venous thromboembolism in postpartum 
women:	multinational	cohort	study.	BMJ.	2016;355:i6253.
 68. Steyerberg EW, Vergouwe Y. Towards better clinical prediction 
models: seven steps for development and an ABCD for validation. 
Eur Heart J. 2014;35:1925–31.
	69.	 Steyerberg	EW,	Pencina	MJ,	Lingsma	HF,	Kattan	MW,	Vickers	AJ,	
Van Calster B. Assessing the incremental value of diagnostic and 
prognostic markers: a review and illustration. Eur J Clin Invest. 
2012;42:216–28.
 70. Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovas-
cular	disease	risk	in	the	general	population:	systematic	review.	BMJ.	
2016;353:i2416.
	71.	 Blondon	M,	Spirk	D,	Kucher	N,	et	al.	Abstract:	external	validation	
and comparison of the improve risk assessment model with the 
Geneva	Risk	Assessment	Model	in	the	ESTIMATE	Cohort.	Res	Pract	
Thromb Haemost. 2017;1:180.
	72.	 Moons	 KG,	 Altman	 DG,	 Vergouwe	 Y,	 Royston	 P.	 Prognosis	 and	
prognostic research: application and impact of prognostic models 
in	clinical	practice.	BMJ.	2009;338:b606.
 73. Foundation for Pharmaceutical Statistics. 3,5% vrouwen tussen 
45-60 jaar krijgt hormoontherapie. 2014. [updated 2017 November 
1]	 Available	 from	 https://www.sfk.nl/publicaties/PW/2014/3-5-
vrouwen-tussen-45-60-jaar-krijgt-hormoontherapie.
 74. van Oostrom SH, Gijsen R, Stirbu I, et al. Time trends in prev-
alence of chronic diseases and multimorbidity not only due to 
aging: data from general practices and health surveys. PLoS ONE. 
2016;11:e0160264.
 75. World Health Organization. Global status report on noncommuni-
cable diseases. Geneva: WHO; 2014.
	76.	 Roser	 M.	 Human	 height	 2017.	 [updated	 1	 November	 2017].	
Available from https://www.OurWorldInData.org.
 77. Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. 
Mortality	and	causes	of	death	in	families	with	the	factor	V	Leiden	
mutation (resistance to activated protein C). Blood. 1997;89:1963–7.
	78.	 van	Mens	TE,	Levi	M,	Middeldorp	S.	Evolution	of	factor	V	Leiden.	
Thromb Haemost. 2013;110:23–30.
	79.	 Lijfering	WM,	Rosendaal	FR,	Cannegieter	SC.	Risk	factors	 for	ve-
nous thrombosis - current understanding from an epidemiological 
point of view. Br J Haematol. 2010;149:824–33.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article:	Scheres	LJJ,	Lijfering	WM,	
Cannegieter SC. Current and future burden of venous 
thrombosis: Not simply predictable. Res Pract Thromb Haemost. 
2018;2:199–208. https://doi.org/10.1002/rth2.12101
